Targeted nonviral gene therapy in prostate cancer.
Targeted nonviral gene therapy in prostate cancer.
复制标题
DOI：
10.2147/ijn.s139080
复制
发表时间：
2018
影响因子：
8
通讯作者：
Dufès C
中科院分区：
文献类型：
--
作者：
Altwaijry N;Somani S;Dufès C
前列腺癌是世界范围内男性中第二大最常见的癌症。治疗选择仅限于乳房切除术，激素治疗和放射治疗，这些治疗通常具有有害的副作用，并且根据疾病的阶段而改变其疗效。在新的实验策略中，基因治疗对前列腺癌的治疗有很大的希望。然而，其使用目前受到缺乏能够在静脉内施用后选择性地将治疗基因递送至肿瘤而没有重大缺点的递送系统的限制。为了解决这个问题，已经开发了广泛的非病毒递送方法，以将基于DNA的治疗剂特异性地递送至其作用部位。本文综述了用于向前列腺癌细胞递送治疗性DNA的各种非病毒递送策略和基因治疗概念，并重点介绍了迄今为止取得的最新治疗进展。
Prostate cancer is the second-most widespread cancer in men worldwide. Treatment choices are limited to prostatectomy, hormonal therapy, and radiotherapy, which commonly have deleterious side effects and vary in their efficacy, depending on the stage of the disease. Among novel experimental strategies, gene therapy holds great promise for the treatment of prostate cancer. However, its use is currently limited by the lack of delivery systems able to selectively deliver the therapeutic genes to the tumors after intravenous administration without major drawbacks. To remediate this problem, a wide range of nonviral delivery approaches have been developed to specifically deliver DNA-based therapeutic agents to their site of action. This review provides an overview of the various nonviral delivery strategies and gene therapy concepts used to deliver therapeutic DNA to prostate cancer cells, and focuses on recent therapeutic advances made so far.